Microbix Biosystems Inc.

As always, even though we're not working off a presentation, this session will contain forward-looking statements. If you'd like to know more about those, you can find them on the presentation on the website, which was updated this morning, so feel free to check that out. And as I mentioned, there will be questions, so feel free to input your questions in the Q&A box, or you can email them to me. With all of that out of the way, I'd like to introduce Cameron Groom, CEO. Hi, Cameron.

Good morning, Deborah. Good morning, everyone. Thank you all for joining us. And I'll in turn introduce Jim Curry, our Chief Financial Officer, and Ken Hughes, our Chief Operating Officer, who are also on the call today with us. So, great. I guess, Deborah, I'll launch in. I mean... This is to discuss principally our results for Q4 and the full year of fiscal 2023. That's the quarter and year ended September 30th, 2023, which capped off what I would call a year that was both challenging and fulfilling. We successfully adapted to post-pandemic conditions. We added a number of important new customers and products. We signed a fully funded redevelopment deal for our biological drug, kinetic urokinase, and we maintained our financial strength. However, we did see a pause in our sales growth in 2023 due to to a lack of new orders for our DXTM viral transport medium, which we've been selling for about 5 million a year for the previous two years, and net of other new revenue and expenses led us to a small net loss for the full year of fiscal 2023. But again, in light of the changes that we've been under, we're taking and the investments we're making to support the longer-term growth of the business, I think we're satisfied with that result in light of the challenges that we face through the year. I might ask Jim now to speak a little bit about the top line, gross margins, net earnings, influences of the year, and just touch on Q4 and the full fiscal year, if you don't mind, Jim. Jim, we'll have to get you off mute. It'll be more compelling if we do.

I hadn't even noticed that. Thank you, Ken.